{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:57:01Z","timestamp":1781002621721,"version":"3.54.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Nephrology of the Universitair Ziekenhuis Brussel"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Hyperoxaluria is an important risk factor for kidney stone formation. Currently available treatment options for idiopathic hyperoxaluria have limited efficacy and are difficult to maintain in the long-term. Preclinical data suggested that lanthanum carbonate (LaCa) might efficiently bind oxalate. In this multicenter, open-label, dose\u2013response study, we assessed the efficacy and safety of LaCa in the reduction of urinary oxalate excretion in stone formers with idiopathic hyperoxaluria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Stone formers with urinary oxalate excretion &amp;gt;45\u00a0mg\/24\u00a0h were treated with LaCa at a dose of 750\u00a0mg daily during a first 14-day treatment period, followed by a second 14-day treatment period with 1500\u00a0mg LaCa daily. The study was powered for the primary efficacy endpoint of detecting a\u00a0\u226520% urinary oxalate excretion reduction after the first treatment period (AFTP). Secondary endpoints were the incremental reduction of urinary oxalate excretion with LaCa dose increase to 1500\u00a0mg during the second treatment period and the effect on serum phosphate and urinary phosphate excretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-four patients started the study, 42 completed the 2 months follow-up. LaCa treatment with both the 750 and 1500\u00a0mg dose had no effect on urinary oxalate excretion [52.0\u00a0mg\/24\u00a0h at baseline (BL), 49.1\u00a0mg\/24\u00a0h AFTP (P\u00a0=\u00a0.25), and 52.6\u00a0mg\/24\u00a0h after second treatment period (ASTP; P\u00a0=\u00a0.01 compared to AFTP, P\u00a0=\u00a0.86 compared to BL)]. Urinary phosphate\/creatinine ratio and fractional excretion (FE) of phosphate decreased significantly after treatment with 1500\u00a0mg LaCa (17.1\u00a0mmol\/g at BL, 15.2\u00a0mmol\/g ASTP, P\u00a0=\u00a0.003 for urinary phosphate\/creatinine ratio and 16.6% at BL, 14.7% ASTP, P\u00a0=\u00a0.002 for FE phosphate), while LaCa had no effect on serum phosphate (0.97\u00a0mmol\/l at BL, 0.95\u00a0mmol\/l ASTP, P\u00a0=\u00a0.29).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short-term treatment with LaCa at doses up to 1500\u00a0mg did not reduce urinary oxalate excretion in stone formers with idiopathic hyperoxaluria. Urinary phosphate excretion decreased without effect on serum phosphate.<\/jats:p>\n                    <jats:p>Clinical trial registration number (ClinicalTrials.gov) NCT03346369<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag103","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:46:12Z","timestamp":1778154372000},"source":"Crossref","is-referenced-by-count":0,"title":["Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9546-8164","authenticated-orcid":false,"given":"Els","family":"Van\u00a0de\u00a0Perre","sequence":"first","affiliation":[{"name":"Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]},{"name":"Kidney Diseases, Dialysis & Transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tielemans","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]},{"name":"Kidney Diseases, Dialysis & Transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"De\u00a0Clerck","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]},{"name":"Kidney Diseases, Dialysis & Transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Pozdzik","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Kidney Stone Clinic, University Hospital Brugmann , Brussels ,","place":["Belgium"]},{"name":"Faculty of Medicine, Universit\u00e9 Libre de Bruxelles (ULB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Durieux","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Centre Hospitalier Wallonie Picarde, Site IMC-Tournai , Tournai ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Boesmans","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Centre Hospitalier Wallonie Picarde, Site IMC-Tournai , Tournai ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Tielens","sequence":"additional","affiliation":[{"name":"General Chemistry (ALGC) - Materials Modelling Group, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"van\u00a0Hooland","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Algemeen Ziekenhuis Sint-Lucas Gent, Campus Sint-Lucas , Gent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"D\u2019Haese","sequence":"additional","affiliation":[{"name":"Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp , Antwerp ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Blust","sequence":"additional","affiliation":[{"name":"Systemic Physiological and Ecotoxicological Research, Department of Biology, University of Antwerp , Antwerp ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Cotton","sequence":"additional","affiliation":[{"name":"Laboratoire Hospitalier Universitaire Bruxelles (LHUB-ULB), Department of Clinical Chemistry, Universit\u00e9 Libre de Bruxelles (ULB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-3233","authenticated-orcid":false,"given":"Karl Martin","family":"Wissing","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]},{"name":"Kidney Diseases, Dialysis & Transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB) , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026060905570276900_bib1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.eururo.2012.03.052","article-title":"Urologic Diseases in America Project. Prevalence of kidney stones in the United States","volume":"62","author":"Scales","year":"2012","journal-title":"Eur Urol"},{"key":"2026060905570276900_bib2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1442-2042.2004.00990.x","article-title":"Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India","volume":"12","author":"Ansari","year":"2005","journal-title":"Int J Urol"},{"key":"2026060905570276900_bib3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00300021","article-title":"Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy","volume":"23","author":"Daudon","year":"1995","journal-title":"Urol Res"},{"key":"2026060905570276900_bib4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/end.2015.0676","article-title":"Prevalence of hyperoxaluria in urinary stone formers: chronological and geographical trends and a literature review","volume":"30","author":"Spradling","year":"2016","journal-title":"J Endourol"},{"key":"2026060905570276900_bib5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/sj.ki.5002708","article-title":"24-h uric acid excretion and the risk of kidney stones","volume":"73","author":"Curhan","year":"2008","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib6","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/ki.2010.310","article-title":"Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation","volume":"78","author":"Lieske","year":"2010","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJMoa010369","article-title":"Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria","volume":"346","author":"Borghi","year":"2002","journal-title":"N Engl J Med"},{"key":"2026060905570276900_bib8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0022-5347(06)00565-9","article-title":"Effect of high and low calcium diets on stone forming risk during liberal oxalate intake","volume":"176","author":"Matsumoto","year":"2006","journal-title":"J Urol"},{"key":"2026060905570276900_bib9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1464-410X.2008.08170.x","article-title":"Evidence for durable kidney stone prevention over several decades","volume":"103","author":"Parks","year":"2009","journal-title":"BJU Int"},{"key":"2026060905570276900_bib10","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.juro.2012.12.004","article-title":"Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats","volume":"189","author":"Robijn","year":"2013","journal-title":"J Urol"},{"key":"2026060905570276900_bib11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3390\/nano11071763","article-title":"In search of an efficient complexing agent for oxalates and phosphates: a quantum chemical study","volume":"11","author":"Vekeman","year":"2021","journal-title":"Nanomaterials"},{"key":"2026060905570276900_bib12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00424-022-02691-x","article-title":"Phosphate intake, hyperphosphatemia, and kidney function","volume":"474","author":"Rubio-Aliaga","year":"2022","journal-title":"Pflugers Arch"},{"key":"2026060905570276900_bib13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ndt\/gfh693","article-title":"Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study","volume":"20","author":"Al-Baaj","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"2026060905570276900_bib14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0272-6386(03)00554-7","article-title":"Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia","volume":"42","author":"Joy","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026060905570276900_bib15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5414\/CNP63461","article-title":"Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease","volume":"63","author":"Chiang","year":"2005","journal-title":"Clin Nephrol"},{"key":"2026060905570276900_bib16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4103\/0253-7613.56074","article-title":"Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease","volume":"41","author":"Scaria","year":"2009","journal-title":"Indian J Pharmacol"},{"key":"2026060905570276900_bib17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2215\/CJN.02830608","article-title":"Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial","volume":"4","author":"Sprague","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060905570276900_bib18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2369-15-71","article-title":"Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial","volume":"15","author":"Ure\u00f1a-Torres","year":"2014","journal-title":"BMC Nephrol"},{"key":"2026060905570276900_bib19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/ndt\/gfq419","article-title":"Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease","volume":"26","author":"Isakova","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026060905570276900_bib20","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026060905570276900_bib21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.34067\/KID.0000000000000465","article-title":"Effect of lanthanum carbonate on serum phosphate, oxidative stress, and vascular dysfunction in CKD: a mechanistic randomized controlled trial","volume-title":"Kidney360","author":"Jovanovich","year":"2024"},{"key":"2026060905570276900_bib22","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1681\/ASN.2012030223","article-title":"Effects of phosphate binders in moderate CKD","volume":"23","author":"Block","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026060905570276900_bib23","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1681\/ASN.2020040411","article-title":"A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026060905570276900_bib24","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1097\/01.ASN.0000133022.32912.95","article-title":"Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?","volume":"15","author":"Behets","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026060905570276900_bib25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5414\/CNP63127","article-title":"Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats","volume":"63","author":"Damment","year":"2005","journal-title":"Clin Nephrol"},{"key":"2026060905570276900_bib26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/000456328702400407","article-title":"The variability and dietary dependence of urinary oxalate excretion in recurrent calcium stone formers","volume":"24","author":"Brown","year":"1987","journal-title":"Ann Clin Biochem"},{"key":"2026060905570276900_bib27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ki.1993.253","article-title":"Relationship of protein intake to urinary oxalate and glycolate excretion","volume":"44","author":"Holmes","year":"1993","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib28","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","article-title":"Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up","volume":"21","author":"Spasovski","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026060905570276900_bib29","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1046\/j.1523-1755.63.s85.18.x","article-title":"A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients","volume":"63","author":"D\u2019Haese","year":"2003","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of urinary oxalate excretion with the risk of chronic kidney disease progression","volume":"179","author":"Waikar","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026060905570276900_bib31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1681\/ASN.2020121793","article-title":"High oxalate concentrations correlate with increased risk for sudden cardiac death in dialysis patients","volume":"32","author":"Pfau","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026060905570276900_bib32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1523-1755.2001.00488.x","article-title":"Contribution of dietary oxalate to urinary oxalate excretion","volume":"59","author":"Holmes","year":"2001","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib33","first-page":"S329","article-title":"Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate","volume":"10","author":"Hesse","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026060905570276900_bib34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.juro.2007.11.062","article-title":"Use of sevelamer hydrochloride as an oxalate binder","volume":"179","author":"Lieske","year":"2008","journal-title":"J Urol"},{"key":"2026060905570276900_bib35","doi-asserted-by":"publisher","first-page":"EVIDoa2100053","DOI":"10.1056\/EVIDoa2100053","article-title":"Randomized placebo-controlled trial of reloxaliase in enteric hyperoxaluria","volume":"1","author":"Lieske","year":"2022","journal-title":"NEJM Evid"},{"key":"2026060905570276900_bib36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/ki.2013.104","article-title":"The role of oxalobacter formigenes colonization in calcium oxalate stone disease","volume":"83","author":"Siener","year":"2013","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.kint.2019.02.012","article-title":"Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis","volume":"96","author":"Miller","year":"2019","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.kint.2019.03.020","article-title":"Gut microbiome and kidney stone disease: not just an Oxalobacter story","volume":"96","author":"Ticinesi","year":"2019","journal-title":"Kidney Int"},{"key":"2026060905570276900_bib39","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2215\/CJN.00600207","article-title":"A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria","volume":"2","author":"Goldfarb","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026060905570276900_bib40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00240-009-0177-5","article-title":"Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients","volume":"37","author":"Ferraz","year":"2009","journal-title":"Urol Res"},{"key":"2026060905570276900_bib41","first-page":"503","article-title":"A targeted release capsule of lanthanum carbonate: a new efficient cheap treatment for primary hyperoxalurias","volume":"10","author":"De\u00a0Broe","year":"2024","journal-title":"KI Rep"},{"key":"2026060905570276900_bib42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.ackd.2010.11.004","article-title":"Intestinal phosphate transport","volume":"18","author":"Sabbagh","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026060905570276900_bib43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1113\/jphysiol.2007.150565","article-title":"The role of SLC26A6-mediated chloride\/oxalate exchange in causing susceptibility to nephrolithiasis","volume":"586","author":"Soleimani","year":"2008","journal-title":"J Physiol"},{"key":"2026060905570276900_bib44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.juro.2016.01.093","article-title":"In silico screening and molecular dynamic study of nonsynonymous single nucleotide polymorphisms associated with kidney stones in the SLC26A6 gene","volume":"196","author":"Lu","year":"2016","journal-title":"J Urol"},{"key":"2026060905570276900_bib45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026060905570276900_bib46","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026060905570276900_bib47","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ekir.2025.03.031","article-title":"PHYOX3: nedosiran long-term safety and efficacy in patients with primary hyperoxaluria type 1","volume":"10","author":"Lieske","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026060905570276900_bib48","article-title":"Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3 (CRYSTAL)","author":"National Institutes of Health, National Library of Medicine, National Center for Biotechnology Information"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag103\/68244566\/gfag103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag103\/68244566\/gfag103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:57:24Z","timestamp":1780999044000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag103\/8671975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag103","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"article-number":"gfag103"}}